Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small-cell lung cancer.

David M Jackman1, Bruce E Johnson

  • 1Dana Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. djackman@partners.org

Lancet (London, England)
|October 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical validation of tissue and liquid companion diagnostics for BRAF V600E detection in non-small cell lung cancers from the PHAROS study.

Cancer research communications·2026
Same author

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

medRxiv : the preprint server for health sciences·2026
Same author

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.

Cancer·2026
Same author

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.

Future oncology (London, England)·2026
Same author

Tumor genomics in patients younger than 40 years of age with metastatic breast cancer.

NPJ precision oncology·2026
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
See all related articles

Small-cell lung cancer (SCLC) is an aggressive malignancy linked to smoking with early spread. Treatment involves chemotherapy, radiation, and prophylactic cranial irradiation for complete remission to manage brain metastases.

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Small-cell lung cancer (SCLC) is a highly aggressive malignancy.
  • SCLC is strongly associated with cigarette smoking.
  • Early dissemination and metastasis are characteristic of SCLC.

Purpose of the Study:

  • To provide an overview of the diagnosis, staging, and treatment of small-cell lung cancer.
  • To highlight key considerations for managing SCLC patients.

Main Methods:

  • Diagnosis relies on bronchoscopic biopsy and expert pathological review.
  • Staging involves comprehensive imaging to detect distant disease.
  • Treatment strategies are based on disease stage (limited or extensive).

Main Results:

Related Experiment Videos

  • Limited-stage SCLC is treated with etoposide, cisplatin, and concurrent chest irradiation.
  • Prophylactic cranial irradiation is recommended for patients achieving complete remission.
  • Extensive-stage SCLC is managed with combination chemotherapy (e.g., etoposide and cisplatin).

Conclusions:

  • Treatment protocols for SCLC vary based on disease stage.
  • Close monitoring for brain metastases and secondary primary tumors is crucial for long-term survivors.
  • Multidisciplinary expertise is essential for optimal SCLC patient management.